Analysts Set Halozyme Therapeutics Inc. (HALO) PT at $16.13
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) have been assigned an average rating of “Buy” from the eight brokerages that are covering the company. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $16.13.
HALO has been the subject of a number of recent research reports. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $15.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, June 23rd. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors increased its stake in shares of Halozyme Therapeutics by 2.5% in the first quarter. BlackRock Fund Advisors now owns 4,302,729 shares of the biopharmaceutical company’s stock valued at $40,747,000 after buying an additional 104,120 shares in the last quarter. BlackRock Group LTD increased its stake in shares of Halozyme Therapeutics by 11.2% in the first quarter. BlackRock Group LTD now owns 128,945 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 12,956 shares in the last quarter. Bellevue Group AG acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at about $3,011,000. California State Teachers Retirement System increased its stake in shares of Halozyme Therapeutics by 1.4% in the second quarter. California State Teachers Retirement System now owns 228,638 shares of the biopharmaceutical company’s stock valued at $1,973,000 after buying an additional 3,260 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of Halozyme Therapeutics by 8.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 66,700 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 5,000 shares in the last quarter. 80.41% of the stock is owned by institutional investors.
Halozyme Therapeutics (NASDAQ:HALO) opened at 10.88 on Monday. The company’s 50-day moving average is $11.23 and its 200-day moving average is $10.12. Halozyme Therapeutics has a 12 month low of $6.96 and a 12 month high of $18.65. The company’s market cap is $1.39 billion.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. Halozyme Therapeutics had a negative return on equity of 234.15% and a negative net margin of 44.90%. The firm earned $33.30 million during the quarter, compared to the consensus estimate of $29.94 million. During the same quarter in the prior year, the firm posted $0.02 EPS. The business’s revenue was down 23.3% on a year-over-year basis. On average, equities research analysts anticipate that Halozyme Therapeutics will post ($0.91) earnings per share for the current year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.